

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

NAME	MS KRATIKA CHOUDHARY	AGE	30YRS	SEX	FEMALE
REF BY	MEDIWHEEL	DATE	12/08/2023	REG NO	
	ECHOCARD	IOGRAM RE	PORT		
WINDO	W- POOR/ADEQUATE/GOODVALV	E			
	NODAMA	TRICI	ICDID	NORMA	1

		LCITC	CARDIOGIA	AIVI ILLI OILI			
WINDOW- PO	OR/ADEQU	ATE/GOO	DDVALVE				
MITRAL	N	IORMAL		TRICUSPID		NORMA	L
AORTIC	N	IORMAL		PULMONARY		NORMA	L
2D/M-MOD							
IVSD mm	8.1		IVSS mm	11.8	AORTA	mm	21.6
LVID mm	41.3		LVIS mm	25.7	LA mm		25.0
LVPWD mm	9.1		LVPWS mm	12.5	EF%		60%
CHAMBERS							
LA		NOI	RMAL	RA		NOR	RMAL
LV		NOI	RMAL	RV		NOF	RMAL
PERICARDIUM		NOI	RMAL				
DOPPLER STUI	DY MITRAL						
PEAK VELOCITY	Y m/s E/A	1.20	0/0.82	PEAK GRADIANT MmHg			
MEAN VELOCITY m/s				MEAN GRA	MEAN GRADIANT MmHg		
MVA cm2 (PLA	NITMETER	Y)	A STATE OF THE PARTY OF THE PAR	MVA cm2 ((PHT)	4	
MR						7	
AORTIC							Later Fig.
PEAK VELOCITY	Y m/s	1.34	1	PEAK GRAD	DIANT MmHg		
MEAN VELOCIT	TY m/s			MEAN GRA	MEAN GRADIANT MmHg		
AR			ARIN				
TRICUSPID			Aller				
PEAK VELOCITY m/s		0.50	5	PEAK GRAD	DIANT MmHg		
MEAN VELOCI	TY m/s	1	VAIC	MEAN GRA	DIANT MmH	g	
TR		1	VVC	PASP mmH	lg O O		
PULMONARY	LEDGET				THE BULL		
PEAK VELOCIT	Y m/s	0.9	5 0	PEAK GRAD	DIANT MmHg		

MEAN GRADIANT MmHg

RVEDP mmHg

IMPRESSION

MEAN VELOCITY m/s

NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION

- **NO RWMA LVEF 60%**
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- **NORMAL VALVULAR ECHO**
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- **IVC NORMAL**

CONCLUSION: FAIR LV FUNCTION.

Cardiologist



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563



Name : Ms. KRATIKA CHOUDHARY

Age/Gender: 29 Y 6 M/Female Patient ID : 012308120031

BarcodeNo:10095408

Referred By: Self

Registration No: 23551

Registered : 12/Aug/2023 09:30AM

Analysed : 12/Aug/2023 02:52PM

Reported : 12/Aug/2023 02:52PM Panel : MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

wellness

*** End Of Report ***

Page 1 of 1



Dr. Needa Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14853



Aakriti Lahs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

: Ms. KRATIKA CHOUDHARY Name

Age/Gender: 29 Y 6 M/Female Patient ID : 012308120031

BarcodeNo: 10095408

Referred By: Self

Registration No: 23551

: 12/Aug/2023 09:30AM Registered

: 12/Aug/2023 11:42AM Analysed

Reported : 12/Aug/2023 11:42AM : MEDI WHEEL (ARCOFEMI

Panel HEALTHCARE LTD)

USG: WHOLE ABDOMEN (Female)

: Is normal in size, shape and echogenecity. LIVER

The IHBR and hepatic radicals are not dilated.

No evidence of focal echopoor/echorich lesion seen. Portal vein diameter and Common bile duct normal in size

: Is normal in size, shape and echotexture. Walls are smooth and GALL

BLADDER regular with normal thickness. Two calculi measuring 12.2 mm and 10.2 mm size seen in GB lumen.

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated. : Is normal in size, shape and echogenecity. Spleenic hilum is not dilated. SPLEEN

KIDNEYS: Right Kidney:-Size: 97 x 31 mm, Left Kidney:-Size: 98 x 46 mm.

Bilateral Kidneys are normal in size, shape and echotexture, corticomedullary differentiation is fair and ratio appears normal.

Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.

URINARY: Bladder walls are smooth, regular and normal thickness.

BLADDER: No evidence of mass or stone in bladder lumen.

: Uterus is anteverted with normal in size shape & echotexture. **UTERUS**

Uterine muscular shadows normal echopattern. Endometrium is normal and centrally placed with size: 10 mm.

No evidence of mass lesion is seen. Size of uterus: 68 x 41 x 31 mm.

Both the ovaries are normal in size shape and echotexture. ADNEXA :

No mass lesion/ polycystic ovarian cyst is seen.

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.

NO evidence of lymphadenopathy or mass lesion in retroperitoneum.

Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION: Cholelithiasis


*** End Of Report ***

Page 1 of 1

Dr. Neera Mehta M.B.B.S., D.M.R.D.

RMCNO.005807/14853









CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WH001027**PATIENT ID: KRATF12029**4**251

CLIENT PATIENT ID: 012308120031 ABHA NO : AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED :12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status Final Results Biological Reference Interval Units

H	IAEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BI	ELOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD: CYANIDE FREE DETERMINATION	11.9 Low	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	4.74	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	8.70	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: ELECTRONIC IMPEDANCE	241	150 - 410	thou/μL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	38.1	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	80.0 Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	25.2 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	31.4 Low	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	13.9	11.6 - 14.0	%
MENTZER INDEX	16.9		
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	11.3 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	62	40 - 80	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	02	40 - 00	70
LYMPHOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	28	20 - 40	%

03

A.

MONOCYTES

Dr. Akansha Jain Consultant Pathologist



2 - 10



Page 1 Of 18

View Details

View Report







REF. DOCTOR: SELF **PATIENT NAME: KRATIKA CHOUDHARY**

CODE/NAME & ADDRESS : C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO : 0251WH001027 PATIENT ID : KRATF120294251 CLIENT PATIENT ID: 012308120031

ABHA NO

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED: 12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
EOSINOPHILS	07 High	1 - 6	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
BASOPHILS	00	0 - 2	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	5.39	2.0 - 7.0	thou/μ L
METHOD: CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	2.44	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.26	0.2 - 1.0	thou/μ L
METHOD: CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.61 High	0.02 - 0.50	thou/μ L
METHOD : CALCULATED PARAMETER	_		
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
	2.2		
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	۷.۷		

Interpretation(s)
BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERN IIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to = The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain **Consultant Pathologist**

Rajasthan, India



Page 2 Of 18











CODE/NAME & ADDRESS : C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WH001027 PATIENT ID : KRATF120294251

CLIENT PATIENT ID: 012308120031

ABHA NO

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED: 12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status Biological Reference Interval <u>Final</u> Results Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

0 - 20mm at 1 hr E.S.R

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminatec malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Polkilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates1

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Akansha Jain Consultant Pathologist





Page 3 Of 18







CODE/NAME & ADDRESS :C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO : 0251WH001027 PATIENT ID : KRATF120294251

CLIENT PATIENT ID: 012308120031

ABHA NO

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED: 12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status Results Biological Reference Interval Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE O **ABO GROUP**

METHOD: TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of rec blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,C or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist** Page 4 Of 18















PATIENT NAME: KRATIKA CHOUDHARY

CODE/NAME & ADDRESS :C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

REF. DOCTOR: SELF

ACCESSION NO : 0251WH001027 PATIENT ID : KRATF120294251

CLIENT PATIENT ID: 012308120031

ABHA NO

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED: 12/08/2023 12:37:35

REPORTED :12/08/2023 15:16:31

Test Report Status Results Biological Reference Interval Units <u>Final</u>

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)

METHOD: GLUCOSE OXIDASE

97

74 - 99

mg/dL

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD HBA1C

5.3

Non-diabetic: < 5.7

Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0

(ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG)

METHOD: CALCULATED PARAMETER

< 116.0

mg/dL

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

99

105.4

70 - 140

mg/dL

LIPID PROFILE, SERUM

METHOD: GLUCOSE OXIDASE

CHOLESTEROL, TOTAL

207 High

< 200 Desirable

mg/dL

200 - 239 Borderline High >/= 240 High

METHOD: CHOLESTEROL OXIDASE

TRIGLYCERIDES

55

< 150 Normal

mg/dL

150 - 199 Borderline High

200 - 499 High

>/=500 Very High

METHOD: LIPASE/GPO-PAP NO CORRECTION

Dr. Akansha Jain **Consultant Pathologist**



Page 5 Of 18











CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WH001027**PATIENT ID: KRATF120294251
CLIENT PATIENT ID: 012308120031

ABHA NO :

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED :12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status <u>Final</u>	Results	Biological Reference Interval	Units
HDL CHOLESTEROL	60	< 40 Low >/=60 High	ng/dL
METHOD: DIRECT CLEARANCE METHOD			
CHOLESTEROL LDL	136 High	< 100 Optimal m 100 - 129	ng/dL
		Near optimal/ above optimal	
		130 - 159	
		Borderline High 160 - 189 High	
		>/= 190 Very High	
NON HDL CHOLESTEROL	147 High	· · · · · · · · · · · · · · · · · · ·	ng/dL
		Borderline High: 160 - 189	
		High: 190 - 219 Very high: > or = 220	
METHOD: CALCULATED PARAMETER		vary mgm. > or = 220	
VERY LOW DENSITY LIPOPROTEIN	11.0	= 30.0</td <td>ng/dL</td>	ng/dL
CHOL/HDL RATIO	3.5	3.3 - 4.4	
		Low Risk	
		4.5 - 7.0	
		Average Risk 7.1 - 11.0	
		Moderate Risk	
		> 11.0	
		High Risk	
LDL/HDL RAΠO	2.3	0.5 - 3.0 Desirable/Low Risk	
		3.1 - 6.0 Borderline/Moderate Risk	
		>6.0 High Risk	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	
Extreme risk group	A.CAD with > 1 feature of high risk group
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease



Dr. Akansha Jain Consultant Pathologist





Page 6 Of 18



View Report









CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WH001027**PATIENT ID : KRATF120294251
CLIENT PATIENT ID: 012308120031

ABHA NO :

AGE/SEX :29 Years Female
DRAWN :12/08/2023 09:30:00
RECEIVED :12/08/2023 12:37:35
REPORTED :12/08/2023 15:16:31

Test Report Status Final Results Biological Reference Interval Units

Very High Risk	Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia			
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque			
Moderate Risk	2 major ASCVD risk factors	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors			
Major ASCVD (A	therosclerotic cardiovascular disease) Risk	Factors		
1. Age $>$ or $= 45 \text{ ye}$	ears in males and > or = 55 years in females	Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD		4. High blood pressure		
5. Low HDL				

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
*	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or>	>OR = 50	>OR = 80
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.72	0 - 1	mg/dL
METHOD: DIAZO WITH SULPHANILIC ACID BILIRUBIN, DIRECT	0.19	0.00 - 0.25	mg/dL
METHOD: DIAZO WITH SULPHANILIC ACID BILIRUBIN, INDIRECT	0.53	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER TOTAL PROTEIN	6.8	6.4 - 8.2	g/dL
METHOD: BIURET REACTION, END POINT ALBUMIN	4.1	3.8 - 4.4	g/dL
METHOD: BROMOCRESOL GREEN GLOBULIN	2.7	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO	1.5	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER ASPARTATE AMINOTRANSFERASE(AST/SGOT)	27	0 - 31	U/L
METHOD: TRIS BUFFER NO PSP IFCC / SFBC 37° C			

1

Dr. Akansha Jain Consultant Pathologist





Page 7 Of 18













PATIENT NAME: KRATIKA CHOUDHARY

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR: SELF
ACCESSION NO: 0251WH001027 AGE

: KRATF120294251

CLIENT PATIENT ID: 012308120031

ABHA NO

PATIENT ID

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED :12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

	j	<u> </u>	
Test Report Status <u>Final</u>	Results	Biological Reference Interva	al Units
ALANTHE AMINOTRANCEEDAGE (ALT/CORT)	20	0 - 31	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: TRIS BUFFER NO PSP IFCC / SFBC 37° C	20	0 - 31	0/1
ALKALINE PHOSPHATASE METHOD: AMP OPTIMISED TO IFCC 37° C	73	39 - 117	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC)	14	7 - 32	U/L
LACTATE DEHYDROGENASE	332	230 - 460	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD: UREASE KINETIC	8	5.0 - 18.0	mg/dL
CREATININE, SERUM			
CREATININE METHOD: ALKALINE PICRATE NO DEPROTEINIZATION	0.79	0.6 - 1.2	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO METHOD: CALCULATED PARAMETER	10.13		
URIC ACID, SERUM			
URIC ACID METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE	4.5	2.4 - 5.7	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD: BIURET REACTION, END POINT	6.8	6.4 - 8.3	g/dL

Dr. Akansha Jain Consultant Pathologist



Page 8 Of 18

View Details











CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WH001027**PATIENT ID: KRATF120294251
CLIENT PATIENT ID: 012308120031

ABHA NO :

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED :12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status	Final	Results	Biological Reference Interval Un	ite
rest keport status	<u>rillai</u>	Kesuits	piological Reference Interval On	ILS

ALBUMIN, SERUM

ALBUMIN	4.1	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL CREEK			

GLOBULIN

GLOBULIN	2.7	2.0 - 4.1	q/dL

ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM	140.9	137 - 145	mmol/L
METHOD : ION-SELECTIVE ELECTRODE POTASSIUM, SERUM	4.31	3.6 - 5.0	mmol/L
METHOD : ION-SELECTIVE ELECTRODE CHLORIDE, SERUM	101.1	98 - 107	mmol/L

METHOD: ION-SELECTIVE ELECTRODE

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative.corticosteroids, diuretics.

Dr. Akansha Jain Consultant Pathologist



Page 9 Of 18



View Repor







CODE/NAME & ADDRESS : C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WH001027 : KRATF120294251

CLIENT PATIENT ID: 012308120031 ABHA NO

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED: 12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status Biological Reference Interval **Final** Results Units

Increased in: Massive hemolysis. Increased in: Renal failure, nephrotic Increased in: Dehydration (excessivesweating, severe severe tissue damage, rhabdomyolysis, syndrome, RTA, dehydration, vomiting or diarrhea), diabetes acidosis, dehydration, renal failure, overtreatment with mellitus, diabetesinsipidus, Addison's disease, RTA type IV, saline, hyperparathyroidism, diabetes hyperaldosteronism, inadequate hyperkalemic familial periodic insipidus, metabolic acidosis from water intake. Drugs: steroids, paralysis. Drugs: potassium salts, diarrhea (Loss of HCO3-), respiratory licorice, oral contraceptives. potassium- sparing diuretics, NSAIDs, alkalosis, hyperadrenocorticism. beta-blockers, ACE inhibitors, high-Drugs: acetazolamide, androgens, dose trimethoprim-sulfamethoxazole. hydrochlorothiazide, salicylates. Interferences: Severe lipemia or Interferences: Hemolysis of sample, Interferences: Test is helpful in delayed separation of serum, assessing normal and increased anion hyperproteinemi, if sodium analysis involves a dilution step can cause prolonged fist clenching during blood gap metabolic acidosis and in spurious results. The serum sodium distinguishing hypercalcemia due to drawing, and prolonged tourniquet falls about 1.6 mEq/L for each 100 placement. Very high WBC/PLT counts hyperparathyroidism (high serum may cause spurious. Plasma potassium chloride) from that due to malignancy mg/dL increase in blood glucose.

Interpretation(s)
GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the игіпе.

(Normal serum chloride)

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitanism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency

levels are normal.

diseases(e.g.galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For:**

- . Evaluating the long-term control of blood glucose concentrations in diabetic patients
- 2. Diagnosing diabetes.3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival; Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (010 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate pattform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

recommendec for detecting a hemoglobinopathy
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg., hemolysis and ineffective erythropoiesis), decreased bilirubin excretion obstruction and hepatitis), and abnormal bilirubin metabolism (eg., hereditary and neonatal jaundice). Conjugatec (direct) bilirubin is elevated more than unconjugated







Page 10 Of 18







AGE/SEX



Female

PATIENT NAME: KRATIKA CHOUDHARY REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WH001027 : KRATF120294251 CLIENT PATIENT ID: 012308120031

DRAWN :12/08/2023 09:30:00 RECEIVED: 12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

:29 Years

Test Report Status Biological Reference Interval <u>Final</u> Results Units

ABHA NO

(indirect) bilirubin ın Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin ıs also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scanning of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic

hepatitis, obstruction of bile ducts, cirrhosis. **ALP** is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagéts disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme founcing cell membranes of many bissues mainly in the liver, kidney and pancreas. It is also founcing other bissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be founcing diseases of the liver, billiary system and pancreas. Conditions that increase serum GGT are obstructive

liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. **Total Protein** also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cinhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance, mainutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

Syntrome Causes of decreased levels-Low 2nd make, Oct, Multiple Sciences.

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum

protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cinhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain Consultant Pathologist Page 11 Of 18













REF. DOCTOR: SELF



PATIENT NAME: KRATIKA CHOUDHARY

CODE/NAME & ADDRESS :C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO : 0251WH001027 PATIENT ID : KRATF120294251

CLIENT PATIENT ID: 012308120031

ABHA NO

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED: 12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status Results Biological Reference Interval Units <u>Final</u>

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

PALE YELLOW COLOR

METHOD: GROSS EXAMINATION

CLEAR APPEARANCE

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

PH	6.0	4.7 - 7.5
rn	0.0	4.7 - 7.3

METHOD: DOUBLE INDICATOR PRINCIPLE

1.003 - 1.035SPECIFIC GRAVITY < = 1.005

METHOD: IONIC CONCENTRATION METHOD PROTEIN NOT DETECTED NEGATIVE

METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

NOT DETECTED **NEGATIVE** GLUCOSE

METHOD: GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

NOT DETECTED KETONES NOT DETECTED

METHOD: SODIUM NITROPRUSSIDE REACTION NOT DETECTED **NEGATIVE** BLOOD

METHOD: PEROCIDASE ANTI PEROXIDASE

NOT DETECTED NOT DETECTED BILIRUBIN METHOD : DIPSTICK

UROBILINOGEN NORMAL NORMAL

METHOD: EHRLICH REACTION REFLECTANCE

NOT DETECTED NOT DETECTED NITRITE

METHOD: NITRATE TO NITRITE CONVERSION METHOD LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

NOT DETECTED NOT DETECTED /HPF RED BLOOD CELLS

METHOD: MICROSCOPIC EXAMINATION /HPF PUS CELL (WBC'S) 3-5 0 - 5

METHOD: DIPSTICK, MICROSCOPY

Dr. Akansha Jain

Consultant Pathologist





Page 12 Of 18











CODE/NAME & ADDRESS : C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WH001027 PATIENT ID : KRATF120294251 CLIENT PATIENT ID: 012308120031

ABHA NO

AGE/SEX :29 Years Female :12/08/2023 09:30:00 DRAWN RECEIVED: 12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

	j	i	
Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
EPITHELIAL CELLS	3-5	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions				
Proteins	Inflammation or immune illnesses				
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment				
Glucose	Diabetes or kidney disease				
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst				
Urobilinogen	Liver disease such as hepatitis or cirrhosis				
Blood	Renal or genital disorders/trauma				
Bilirubin	Liver disease				
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), uring tract infection and glomerular diseases				
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis eithe acute or chronic, polycystic kidney disease, urolithiasis, contamination genital secretions				
Epithelial cells Urolithiasis, bladder carcinoma or hydronephrosis, ureteric bladder catheters for prolonged periods of time					
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein				
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, rena diseases				

Dr. Akansha Jain **Consultant Pathologist**



Page 13 Of 18















CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WH001027**PATIENT ID: KRATF120294251
CLIENT PATIENT ID: 012308120031

ABHA NO :

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED :12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status Final Results Biological Reference Interval Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice		
Uric acid	arthritis		
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.		
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis		

Dr. Akansha Jain Consultant Pathologist





Page 14 Of 18

View Detaile





DIAGNOSTIC REPORT





PATIENT NAME: KRATIKA CHOUDHARY

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR: SELF
ACCESSION NO: 0251WH001027 AGE

PATIENT ID : KRATF120294251

CLIENT PATIENT ID: 012308120031 ABHA NO : AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED :12/08/2023 12:37:35

REPORTED :12/08/2023 15:16:31

Test Report Status Final Results Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD

SAMPLE NOT RECEIVED

Dr. Akansha Jain Consultant Pathologist





Page 15 Of 18

View Details

View Report











PATIENT NAME: KRATIKA CHOUDHARY

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 REF. DOCTOR: SELF
ACCESSION NO: 0251WH001027 AGE

PATIENT ID : KRATF120294251

CLIENT PATIENT ID: 012308120031

ABHA NO

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED :12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, STOOL

COLOUR

METHOD: GROSS EXAMINATION

SAMPLE NOT RECEIVED

Sidney of

Dr. Abhishek Sharma Consultant Microbiologist





Page 16 Of 18

View Details

View Report









CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WH001027**PATIENT ID: KRATF120294251

CLIENT PATIENT ID: 012308120031 ABHA NO : AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED :12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

Т3	125.94	60.0 - 181.0	ng/dL
METHOD: CHEMILUMINESCENCE			
T4	8.80	4.5 - 10.9	µg/dL
METHOD: CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	1.335	0.550 - 4.780	μΙU/mL
METHOD: CHEMILUMINESCENCE			

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hypothyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism





Page 17 Of 18



View Report











CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WH001027**PATIENT ID: KRATF120294251
CLIENT PATIENT ID: 012308120031

ABHA NO :

AGE/SEX :29 Years Female DRAWN :12/08/2023 09:30:00 RECEIVED :12/08/2023 12:37:35 REPORTED :12/08/2023 15:16:31

Test Report Status <u>Final</u> Results Biological Reference Interval Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain Consultant Pathologist



Page 18 Of 18

/iew Details





